Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 4/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505758 | 0.87 | EGFR (0.52) | ALDH1A1LMNAERBB2EGFRKMT2A | |
| SCHEMBL4460715 | 0.81 | SLC7A5 (0.43) | LMNAPGRARGCKCYP2C19 | |
| SCHEMBL3508731 | 0.81 | ALDH1A1 (0.56) | ALDH1A1LMNAKMT2AMAPTTBXA2R | |
| SCHEMBL13342147 | 0.77 | HDAC8 (0.67) | ALDH1A1LMNAPGRGCKCYP2C9 | |
| SCHEMBL3043953 | 0.77 | ALDH1A1 (0.54) | ALDH1A1LMNAKMT2ACYP2C19 | |
| SCHEMBL2997554 | 0.77 | ALDH1A1 (0.53) | ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL3484176 | 0.76 | EGLN1 (0.38) | MAPT | |
| SCHEMBL3506152 | 0.76 | MRGPRX4 (0.46) | ALDH1A1LMNAERBB2EGFRKMT2A | |
| Hydrochloric Acid SCHEMBL21198410 | 0.75 | ALDH1A1 (0.53) | ALDH1A1LMNAKMT2ACYP2C19 | |
| Hydrochloric Acid SCHEMBL31306628 | 0.75 | ALDH1A1 (0.53) | ALDH1A1LMNAKMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1957495-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | GRK6, FGFR1, PTK6 | ALDH1A1 2073/4885LMNA 3796/4885PGR 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.